An observational study in Sepsis, sponsored by Helwan University. Completed at 1 site in Egypt. Open to participants aged 26 Weeks to 37 Weeks. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Helwan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Sepsis with a site in Egypt — 25 open to participants now, 27 under way, 3 of them phase 3. Sepsis · Egypt.
Among the 106 studies in Sepsis with a site in Egypt, this one is the 55th largest by enrollment of the 55 observational ones that give a count, is one of 14 that started in 2024, is one of 55 observational ones, and was the 106th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →25 of the 106 studies in Sepsis with a site in Egypt are open now. Recruiting first, the newest first:
Menoufia University · Sites in Egypt
Ages 18+
Menoufia University · Sites in Egypt
Ages 1 mo–18 yrs
Ain Shams University · Sites in Egypt
Ages 18+
Alexandria University · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 26 Weeks to 37 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 9 · Phase 4 8
First in 2000; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 80 across the 50 interventional studies, 80 across the 55 observational. Of the 67 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 106 have an industry lead sponsor. The 10 most frequent:
Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.
Helwan University has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
7 of the studies in Sepsis with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04910464Phase 3Assiut UniversityEarly Tranexamic Acid and Modulating the Inflammatory Response in Sepsis | 2027-01-10 |
| NCT07516236Menoufia UniversityDynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock | 2027-01 |
| NCT07706413Menoufia UniversityPlasma Exchange in Children With Severe Sepsis and Septic Shock | 2027-02-28 |
| NCT07795502Sohag UniversityDynamic Infection Kinetics for Early Diagnosis, Monitoring, and Prognostication of Sepsis in Adult Oncology Patients: Evaluating Serial Infection Biomarkers, Blood Culture Kinetics, Treatment Response, Disease Severity, and Clinical Outcomes | 2027-03-07 |
| NCT07030114Assiut UniversityThe Study Seeks to Determine Potential Correlations Between Ventilation and Hematological Alterations, Contributing to a Better Understanding of Its Physiological Effects and Optimizing Patient Management in Critical Care Settings. | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Sepsis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective study evaluating the pharmacokinetics of colistin after IV administration of colistin different doses
4. Scientific committee approval (Was it scientifically approved by the department?) Yes
Date of approval: 2-7-2024
5. Background and Rationale: (Describe the research question and justification for undertaking the study explaining the aspects of novelty in the study) 3. Background and Rationale: Neonatal bacterial sepsis remains one of the major causes of neonatal morbidity and mortality, especially in hospitalized term and preterm neonates all around the world and especially in low- and middle-income countries. An estimated 1.3 million episodes of neonatal sepsis occur annually with 200,000 sepsis-attributable deaths each year worldwide. ("Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017," 2018) The limited therapeutic options against antimicrobial drug-resistant Gram-negative bacteria have led to the development and study of several novel antibacterial agents including β-lactam/β-lactamase inhibitor combinations (BL-BLIs) and the use of old or repurposed antibiotics. (Chiotos, etal.,2020) Colistin is among the very few agents still effective against carbapenem-resistant Gram-negative bacteria. It has been used clinically since the late 1950s but was substituted some decades later by newer antimicrobials owing to reported neurotoxicity and nephrotoxicity. (Bergen, etal., 2006) colistin is considered to be less nephrotoxic compared to aminoglycosides (Conway et al., 2000). It has been demonstrated that colistin may affect renal function when combined with aminoglycosides but not when used as monotherapy (Al-Aloul et al., 2005). It has been shown that colistin can increase serum creatinine levels, but this renal effect is mild and is not usually associated with severe renal effects. Furthermore, it depends on the duration of treatment, whereas a return to normal creatinine levels is observed within one month of discontinuing treatment (Al-Aloul et al., 2005).
Colistin has been recommended by the Infectious Diseases Society of America (IDSA) 2022 guidance for the treatment of MDR-GN bacteria only as an alternate strategy when first line options are not available or tolerated (mainly combination beta-lactamase inhibitors, carbapenems, or monobactam). (Tamma et al., 2022) In low-middle-income countries (LMICs), colistin is the most prevalent antimicrobial and most studies come from these countries. Because of the concomitant use of other antimicrobials with colistin, the severity of the clinical condition in neonates, the lack of case control studies in neonates and infants, and the retrospective character of the studies reported, it is difficult to draw conclusions on the efficacy and safety of colistin in neonates. Renal impairment and electrolyte deficiencies, such as magnesium and potassium possibly related to renal tubulopathy, have been reported in a review of colistin use in neonates. However, concomitant nephrotoxic agents and clinical comorbidities contribute to nephrotoxicity and renal injury. Moreover, evidence of neurotoxicity related to colistin use is rare in neonates (Nakwan, etal.2019).
The increasing problem of the resistance of microorganisms such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae has led researchers to reapply this old drug, especially in cases where there are no other treatment options due to multi-resistant strains. Even though colistin is considered the last line therapy for these microorganisms, several cases of colistin resistance have emerged, particularly against Pseudomonas aeruginosa. Resistance to the other two pathogens, Acinetobacter baumannii and Klebsiella pneumoniae, is variable. It seems to be increasing, especially for Acinetobacter baumannii, whereas resistance to Klebsiella pneumoniae is relatively rare. This phenomenon has been observed in several cases (Ko et al., 2007). It is suggested that the combination of colistin with other antibiotics can minimize the potential for the emergence of resistance with colistin monotherapy against A. baumannii.
There is a paucity of PK data in pediatrics and neonates due to complicated pharmacokinetics, high interpatient variability, and narrow therapeutic indices. Therefore, recommendations for dosage in neonates are challenging. According to a PK study in neonates with normal renal function, the daily dose of CMS should be >150,000 IU/kg/day to achieve an average steady-state plasma colistin concentration (Css, avg) of >1±0.4 µg/mL, with close monitoring of renal function (Nakwan et al., 2016)
. Current colistin dosing regimens result both in a subtherapeutic peak concentration and a prolonged time to steady state, leading to suboptimal and delayed effective treatment. Therefore, strategies involving higher doses and longer dosing intervals along with loading doses have been proposed, in order to attain more effective killing There is limited data about the systemic colistin use in neonatal population. For this reason, a prospective observational study was planned to evaluate the efficacy and safety of colistin in conventional doses and high doses used to treat multidrug-resistant microorganisms in neonatal intensive care unit settings.
Neonates
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospective study evaluating the pharmacokinetics of colistin after intravenous administration of colistimethate sodium (CMS) in the critically ill neonates with Gram-negative bacterial infections and reaching steady state after 4 days (Peak (Cmax) \& trough (Cmin)) comparing two different colistin doses conventional dose 150000 IU/Kg/day divided into three doses and High dose 225000 IU/Kg/day divided into three doses
Drug: Polymyxin E (Colistin)
1. Evaluation of neonatal efficacy of different administered doses of IV colistin in neonatal sepsis. 2. Assessment of colistin related AKI rates in NICU. 3. Development of personalized approach for dose selection in neonatal sepsis 4. Characterize pharmacokinetics parameters in neonates including volume of distribution \& clearance 5. Correlate the pharmacokinetics parameter with microbiological, clinical response and toxicity
1. Evaluation of neonatal efficacy of different administered doses of IV colistin in neonatal sepsis. 2. Assessment of colistin related AKI rates in NICU. 3. Development of personalized approach for dose selection in neonatal sepsis
Time frame: 4 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Mar 2025, 3 months.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's 3 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helwan University